Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC. // JHEP Reports. – URL: https://www.sciencedirect.com/science/article/pii/S258955592600371X?dgcid=rss_sd_all
Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC. JHEP Reports. https://www.sciencedirect.com/science/article/pii/S258955592600371X?dgcid=rss_sd_all
“Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC.” JHEP Reports.
@article{article51159,
title = {Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC},
journal = {JHEP Reports},
url = {https://www.sciencedirect.com/science/article/pii/S258955592600371X?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...